March 12, 2019
Bristol-Myers Squibb and Ono Pharmaceutical said on March 11 that they have filed a supplemental application for their T-cell-specific costimulation modulator Orencia (abatacept) for the prevention of structural damage to joints. When Orencia was approved in 2010, additional clinical studies...read more